Livestrong Cancer Institutes' Patient Reported Outcomes Study (LCI PROs)

The University of Texas System (UT)

Status: Completed

Conditions: Drug Therapy; Neoplasms

Study type: Observational

Funder types: Other

Identifiers

NCT04627077

2017-08-0081

Details and patient eligibility

About

The goal of this study will be to collect baseline patient reported outcome measures at the Livestrong Cancer Institutes (LCI) with the goal of improving quality care and to inform decision making by patients, providers, and researchers for future LCI initiatives.

Full description

This proposed study is a descriptive study of the adult oncology population at the Seton Infusion Center in order to provide information about patient needs and identify areas for further research and resource allocation. The patient reported outcome measures being collected cover the following domains: anxiety, depression, fatigue, physical function, financial toxicity and pain. Patients and caregivers will be informed about the study and given the opportunity to enroll at the time of routine clinic visits at the Dell Seton Medical Center at The University of Texas Seton Infusion Center (SIC). Patients choosing to enroll in the study will be provided informed consent, and then allowed to complete the measures during their clinic visit on an iPad provided by the research staff. After IRB approval for a period of 1-2 months data collection will take place at the SIC clinic at DMS. Upon completion of the measures patients will be asked for an email address and phone number so that a follow up link to survey questions can be sent to them in 3 months.

Enrollment: 121 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient aged 18 years and older, being treated for cancer at the Seton Infusion Clinic
• Patient cognitively and physically able to complete questionnaires on an ipad in English or Spanish.

Exclusion criteria

• -Patient unable to speak English or Spanish as required for study data collection
• Patient cognitively or physically unable to complete measures

Trial design

121 participants in 1 patient group

SIC drug therapy patients

Description:

Patients with a cancer diagnosis currently being treated at SIC clinic